Long-term safety and efficacy data with inhaled pirfenidone (AP01) in the ATLAS open-label extension study up to 240 weeks

Tamera J. Corte, Sébastien Tilleux2, Deepthi K. Nair, Felix A. Woodhead, Meredith Hart, Hao Bao, Craig Conoscenti, Howard M. Lazarus, Margaret L. Wilsher